Latest News and Press Releases
Want to stay updated on the latest news?
-
In Brief: Findings from studies in Türkiye and Ghana presented at ASCAT 19th Annual Scientific Conference demonstrate that the Gazelle™ Hb Variant Test is an effective tool for accurate and...
-
A clinical study demonstrated high accuracy for Hemex Health's beta thalassemia test. It is the only beta thal test for point of care.
-
SAN FRANCISCO and PORTLAND, Ore., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemex Health, Inc., a medical device company based in Portland, Oregon and Mumbai, India, was honored today by AllianceIndus at...
-
PORTLAND, Ore., March 27, 2023 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostic device company focused on expanding healthcare access to underrepresented patient populations, announced it has...
-
New York, USA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Beta Thalassemia Clinical Trials Pipeline Analysis: 22+ Companies are Working to Improve the Treatment Space | DelveInsight The prevalence of...
-
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
-
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
-
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
-
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
-
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...